Review



pima cd4 platform  (Abbott Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Abbott Laboratories pima cd4 platform
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Platform, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pima+cd4+platforms/pmc12824445-48-22-25?v=Abbott+Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 platform - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda"

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    Journal: Journal of the International AIDS Society

    doi: 10.1002/jia2.70075

    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Figure Legend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Techniques Used:

    Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.
    Figure Legend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Techniques Used:



    Similar Products

    pima cd4 platform  (Abbott Laboratories)
    86
    Abbott Laboratories pima cd4 platform
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Platform, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pima+cd4+platforms/pmc12824445-48-22-25?v=Abbott+Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 platform - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    pima cd4 platforms  (Abbott Laboratories)
    90
    Abbott Laboratories pima cd4 platforms
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Platforms, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pima+cd4+platforms/10__1016_slash_s2214___109x_ascii40_24_ascii41_00444___3-7-16-3?v=Abbott+Laboratories
    Average 90 stars, based on 1 article reviews
    pima cd4 platforms - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    cd4 testing pima platform  (Abbott Laboratories)
    90
    Abbott Laboratories cd4 testing pima platform
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Cd4 Testing Pima Platform, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pima+cd4+platforms/nct01810289-7-6-12?v=Abbott+Laboratories
    Average 90 stars, based on 1 article reviews
    cd4 testing pima platform - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Article Snippet: Several devices for point‐of‐care CD4 testing are commercially available, including the BD FACSPresto system (BD Biosciences, Franklin Lakes, NJ, USA) and the PIMA CD4 platform (Abbott, Chicago, IL, USA).

    Techniques:

    Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Article Snippet: Several devices for point‐of‐care CD4 testing are commercially available, including the BD FACSPresto system (BD Biosciences, Franklin Lakes, NJ, USA) and the PIMA CD4 platform (Abbott, Chicago, IL, USA).

    Techniques: